Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-05-23
2006-05-23
Huff, S. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120
Reexamination Certificate
active
07049059
ABSTRACT:
The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.
REFERENCES:
patent: 4830969 (1989-05-01), Holmes
patent: 4843155 (1989-06-01), Chomczynski
patent: 5128247 (1992-07-01), Koller
patent: 5284940 (1994-02-01), Lin et al.
patent: 5346994 (1994-09-01), Chomczynski
patent: 5502166 (1996-03-01), Mishina
patent: 5620852 (1997-04-01), Lin et al.
patent: 5637687 (1997-06-01), Wiggins
patent: 5643767 (1997-07-01), Fischetti et al.
patent: 5654179 (1997-08-01), Lin
patent: 5672696 (1997-09-01), Wang et al.
patent: 5705336 (1998-01-01), Reed et al.
patent: 5707802 (1998-01-01), Sandhu et al.
patent: 5728822 (1998-03-01), Macfarlane
patent: 5777099 (1998-07-01), Mehra
patent: 5945515 (1999-08-01), Chomczynski
patent: 5952202 (1999-09-01), Aoyagi et al.
patent: 5989857 (1999-11-01), Mundschenk
patent: 5998151 (1999-12-01), Johnston et al.
patent: 6010700 (2000-01-01), Richt
patent: 6043354 (2000-03-01), Hillebrand et al.
patent: 6204375 (2001-03-01), Lader
patent: 6207408 (2001-03-01), Essenfeld et al.
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 2002/0090642 (2002-07-01), Johnston et al.
patent: 0 290 144 (1988-09-01), None
patent: WO 90/02203 (1990-03-01), None
patent: WO 95/28489 (1995-10-01), None
patent: WO 97/05248 (1997-02-01), None
patent: WO 97/35034 (1997-09-01), None
patent: WO 98/41648 (1998-09-01), None
Ishikawa Y et al (Japanese Journal of Cancer Research: Gann; Jan. 2000; 91(1):105-112, see abstract only.
Sun HS et al (Br J Haematol. Aug. 2003;122(4):590-9).
Iqbal S, Lenz HJ, “Determinants of prognosis and response to therapy in colorectal cancer,”Curr Oncol Rep. Mar. 2001;3(2):102-8.
Gilmore PM, et al., “The Development and Optimisation of a Quantitative RT-PCR Technique from Formalin-Fixed and Paraffin-Embedded (FFPE) Tissues, Using the Thymidylate Synthase (TS) Gene As a Target,” American Society of Clinical Oncology: 17: Abstract 2159, 1998.
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV, “Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase,” Clin Cancer Res. Apr. 2000;6(4):1322-7.
Kirihara Y, Yamamoto W, Toge T, Nishiyama M, “Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells,” Int J Oncol. Mar. 1999;14(3):551-6.
Nita ME, Tominaga O, Nagawa H, Tsuruo T, Muto T, “Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer,” Hepatogastroenterology, Nov.-Dec. 1998;45(24):2117-22.
Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H, “Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue,” Am J Pathol. Feb. 2001;158(2):419-2.
Gibson, UE, “A novel method for real timequantitative RT-PCR,” Genome Res 6: 995-1001, 1996.
Heid, CA, “Real Time quantitative PCR,” Genome Res 6: 986-994, 1996.
Leichman et al., Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. Oct. 1997;15(10):3223-9.
Schena, Mark et al. “Quantitative Monitoring of Gene Expression Patterns With a Complementary DNA Microarray”, Science (1995) vol. 270:467-470.
Zhao, Nanding et al., “High-Density cDNA Filter Analysis: A Novel Approach for Large-Scale, Quantitative Analysis of Gene Expression”, Gene (1995) vol. 156: 207-213.
Damia G, Guidi G, D'Incalci M, “Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines,” Eur J Cancer, Oct. 1998;34(11):1783-8.
Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M, “Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer,” Gynecol Oncol. Apr. 1997; 65(1):130-7.
Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E., “Expression of excision repair genes in non-malignant bone marrow from cancer patients,” Mutat Res. Jan. 1993;293(2):151-60.
Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E., “ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients,” J Natl Cancer Inst. Oct. 7, 1992;84(19):1512-7.
Metzger R, et al., “ERCC1 mRNA Levels Complement Thymidylate Synthase mRNA Levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy,” J Clin Oncol 16: 309-316, 1998.
Taverna P, Hansson J, Scanlon KJ, Hill BT, “Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity,” Carcinogenesis. Sep. 1994;15(9):2053-6.
Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, Bey P, “Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity,” Br J Cancer. Jul. 1998;78(1):62-8.
Lenz HJ, et al., p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998.
Lenz HJ, et al., Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival, J Clin Oncol 14: 176-182, 1995.
Lenz HJ, et al., p53 and thymidylate synthase gene expressionin untreated stage II colon cancer: association with recurrence, survival, and site. Clin Cancer Res 4: 1227-34, 1998.
Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J, Salonga D, Danenberg KD, Danenberg PV, Beger HG, “Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy,” Cancer Jul. 15, 2000;89(2):288-96.
Gorlick R, Metzger R, Danenberg KD, Salonga D, Miles JS, Longo GS, Fu J, Banerjee D, Klimstra D, Jhanwar S, Danenberg PV, Kemeny N, Bertino JR, “Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma,” J Clin Oncol Apr. 1998;16(4):1465-9.
Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. Aug. 1994;94(2):703-8.
Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. Mar.-Apr. 2000;20(2A):645-52.
Johnston et al., TS Expression from Formalin Fixed Paraffin Embedded (FFPE) tissues using Quantitative RT-PCR correlates with frozen tissue data and predicts for response to 5-FU in metastatic colorectal cancers. American Society of Clinical Oncology: Astract 2383, 1999.
G. Stanta, et al
Huff S.
Kenyon & Kenyon LLP
Response Genetics, Inc.
Yaen C.
LandOfFree
Method of determining a chemotherapeutic regimen based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of determining a chemotherapeutic regimen based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining a chemotherapeutic regimen based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610298